Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 pivotal registrational study of BCB-276

Trial Profile

Phase 2 pivotal registrational study of BCB-276

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCB 276 (Primary)
  • Indications Diffuse intrinsic pontine glioma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 15 May 2025 According to BrainChild Bio media release, BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025
  • 14 Jan 2025 New trial record
  • 07 Jan 2025 According to BrainChild Bio media release, company look forward to the initiation of the BCB-276 pivotal trial by the end of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top